NCT00002086View on ClinicalTrials.gov

A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Zidovudine

DRUG

Zalcitabine

DRUG

Interferon alfa-n1

Trial Locations (13)

11030

North Shore Univ Hosp / Div of Infectious Diseases, Manhasset

20007

Georgetown Univ Med Ctr, Washington D.C.

33140

Stratogen of South Florida, Miami Beach

33612

Univ of South Florida, Tampa

37232

Vanderbilt School of Medicine, Nashville

46202

Infectious Diseases Research Clinic / Indiana Univ Hosp, Indianapolis

67214

Univ of Kansas School of Medicine, Wichita

77030

Baylor College of Medicine, Houston

84132

Univ of Utah School of Medicine, Salt Lake City

94103

ViRx Inc, San Francisco

94903

Marin County Specialty Clinic, San Rafael

97210

Portland Veterans Adm Med Ctr / Rsch & Education Grp, Portland

452670560

Univ of Cincinnati, Cincinnati

Sponsors

Lead Sponsor

Glaxo Wellcome
All Listed Sponsors
lead

Glaxo Wellcome

INDUSTRY

NCT00002086 - A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection | Biotech Hunter | Biotech Hunter